Bone growth stimulator comments
This article was originally published in The Gray Sheet
Executive Summary
FDA requests feedback on a June 2006 recommendation by the agency's Orthopaedic and Rehabilitation Devices Advisory Panel that noninvasive bone growth stimulator products should not be downclassified from Class III (premarket approval) to Class II (special controls) (1"The Gray Sheet" June 5, 2006, p. 7). Comments are due April 16, according to a Jan. 17 Federal Register notice...
You may also be interested in...
FDA Panel Teeters, But Keeps Bone Growth Stimulators Class III
FDA advisory panel members said June 2 that the agency should continue to require clinical trials to ensure the safety and efficacy of medical devices that employ magnetic or electrical signals to help treat certain types of bone fractures and spinal disease
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.